$Bristol-Myers Squibb(BMY)$ rebounds from multiyear low. Undervalued, however this is not a true LT value creating pharma stock. Huge dividend stopped the bleeding. Needs big growth driver going forward. Acquisitions are necessary. Why not entering the huge obesity market?
Image
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
